	Application No.	Applicant(s)	
Notice of Allowability	09/919,703	KRYSTAL ET AL.	
	Examiner	Art Unit	
	Samuel W Liu	1653	
The MAILING DATE of this communication appeal All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RI	(OR REMAINS) CLOSED or other appropriate comm GHTS. This application is	in this application. If not included nunication will be mailed in due course. THI	
1. This communication is responsive to <u>1-6-04</u> .			
 ∑ The allowed claim(s) is/are 1-10,12,19 and 24-27. ∑ The drawings filed on 31 July 2001 are accepted by the Exmitted in the expectation of the expectation. 	raminer		
 4. ☐ Acknowledgment is made of a claim for foreign priority ur a) ☐ All b) ☐ Some* c) ☐ None of the:) or (f).	
 Certified copies of the priority documents have 	e been received.		
2. Certified copies of the priority documents have			
3. Copies of the certified copies of the priority documents have been received in this national stage application from the			
International Bureau (PCT Rule 17.2(a)). * Certified copies not received:			
 5. Acknowledgment is made of a claim for domestic priority u reference was included in the first sentence of the specifica (a) The translation of the foreign language provisional at Acknowledgment is made of a claim for domestic priority u in the first sentence of the specification or in an Application 	ation or in an Application D application has been received and the state of the sta	ata Sheet. 37 CFR 1.78. ed. I/or 121 since a specific reference was inclu	ıded
Applicant has THREE MONTHS FROM THE "MAILING DATE" of below. Failure to timely comply will result in ABANDONMENT of			
7. A SUBSTITUTE OATH OR DECLARATION must be subm INFORMAL PATENT APPLICATION (PTO-152) which give			
 8. CORRECTED DRAWINGS (as "replacement sheets") must be submitted. (a) including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached 1) hereto or 2) to Paper No. (b) including changes required by the proposed drawing correction filed, which has been approved by the Examiner. (c) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No 			
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the margin according to 37 CFR 1.121(d).			
9. DEPOSIT OF and/or INFORMATION about the depo attached Examiner's comment regarding REQUIREMENT FOR T			
Attachment(s)			
1 Notice of References Cited (PTO-892)		formal Patent Application (PTO-152)	
 2 ☐ Notice of Draftperson's Patent Drawing Review (PTO-948) 3 ☐ Information Disclosure Statements (PTO-1449 or PTO/SB/08) 		ummary (PTO-413), Paper No. <u>1-23-04</u> .	
Paper No	⁷), 7⊠ Examiner's	Amendment/Comment	
4☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material	8∏ Examiner's 9∏ Other	Statement of Reasons for Allowance .	

Application/Control Number: 09/919,703

Art Unit: 1653

DETAILED ACTION

This Office action is in response to applicants' amendments filed 6 January 2004, which cancels claim 20, amends claim 1, and adds claims 24-27. The amendments indicated above have been entered. Note that claims 11, 13-18 and 21-23 have ben cancelled (see the applicants' amendment filed 7 July 2003). Alos, applicants' request for extension of time of two months has been entered. The pending claims 1-10, 12, 19 and 24-27 are therefore examined in this Office action.

EXAMINER'S AMENDMENT

An Examiner's Amendment to the record appears below. Should the change and/or additions be unacceptable to Applicant, an amendment may be filed as provided by 37 C.F.R. § 1.312. To ensure consideration of such an amendment, it MUST be submitted no latter than payment of the Issue Fee.

Authorization for this examiner's amendment was given in a telephone interview with Michael Belliveau on January 23, 2004.

Amendments to the claims:

Claim 2 (amended): The method of claim 1, wherein said peptide consists of a peptide sequence of SEQ ID NO:1.

Claim 3 (amended): The method of claim 1, wherein said peptide comprises a peptide sequence of SEQ ID NO:1.

Claim 12 (amended): The method of claim 1, wherein said cell death is associated with a cardiovascular disease.

Claim 19 (amended): After "The method of", change "claim 18" to "claim 12".

Conclusion: Claims 1-10, 12, 19 and 24-27 are allowable over the art of record.

Application/Control Number: 09/919,703

Art Unit: 1653

Page 3

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Samuel Wei Liu, Ph.D. whose telephone number is (571) 272-0949. The Examiner can normally be reached daily except alternate Fridays from 8:30 A.M. to 5:30 P.M. If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Christopher Low, can be reached at (571) 272-0951. The official fax phone number for Technology Center 1600 is (703) 308-4242.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Technology Center 1600 receptionist whose telephone number is (703) 308-0196.

SWL

Samuel W. Liu, Ph.D.

January 23, 2004

KAREN COCHRANE CARLSON, PH.D PRIMARY EXAMINER

fau Cahan Cacher Des